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The aim of this review is to appraise the usage of a newly approved anti-vascular endothelial growth factor (anti-VEGF) fu-
sion protein, aflibercept, in ocular neovascular disorders such as diabetic retinopathy and age-related macular degeneration. 
Aflibercept is a soluble fusion protein, which combines ligand-binding elements taken from the extracellular domains of VEGF 
receptors 1 and 2 fused to the Fc portion of IgG. This protein contains all human amino acid sequences, which minimizes the 
risk for immunogenicity in human patients. In this short review we investigate the available literature and data from clinical 
studies on the efficacy, pharmaceutical and pharmacological properties of aflibercept, and identify its possible advantages over 
commercially available anti-VEGF drugs. Biomed Rev 2014; 25: 59-65
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INTRODUCTION
Diabetic macular edema (DME) is a complication of diabetic 
retinopathy and is a leading cause of blindness. Nowadays 
more people suffering from diabetes are diagnosed with 
DME. Diabetic macular edema, defined as retinal thickening 
within 2 disc diameters of the center of the macula, results 
from retinal microvascular changes that compromise the 
blood-retinal barrier, causing leakage of plasma constituents 
into the surrounding retina and, consequently, retinal edema 
(1). Anti-vascular endothelial growth factor (anti-VEGF) 
drugs and steroids have been introduced as potential alter-
natives to laser photocoagulation, the basis of treatment. 
Chronology of the development of the new drugs is shown 
on Figure 1.
Ocular angiogenesis can be physiological or pathological. 
The physiological ocular angiogenesis is occurring primarily 
during embryonic development (2). Ocular angiogenesis in 
adults is usually pathological and is a major cause of vision 
loss and blindness due to conditions as presented in Table 1.
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Figure 1. Timeline of discovery of therapy for neovascular age-related macular degeneration. CNV, choroidal neovasculariza-
tion; VEGF, vascular endothelial growth factor; PDT, photodynamic therapy.
Table 1. Examples of ophthalmic neovascular disorders
Choroidal neovascularization (CNV) bounded to 




Retinopathy of prematurity. 
Vascular endothelial growth factor (VEGF)-A appears to be 
necessary for growth of blood vessels in a variety of nor-
mal and pathological circumstances (3). The VEGF family 
consists of five related glycoproteins, VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, and placental growth factor 
(PlGF) (4). VEGF has two main receptors in normal bio-
logical systems: VEGFR1 and VEGFR2. VEGFR2 mediates 
most of the endothelial cell proliferating activity of VEGF, 
whereas VEGFR1 mediates other activities of VEGF, such 
as a chemoattraction (5). Both receptors are important for the 
angiogenic-promoting properties of VEGF.
VEGF TRAP-EYE MECHANISM OF ACTION
This new approach to the treatment of wet AMD was de-
veloped to enhance the therapeutic activity – significant 
improvement in visual acuity and reducing frequency of ad-
ministration. Aflibercept/VEGF trap-eye (VTE) is a soluble 
fusion protein, which combines ligand-binding elements tak-
en from the second binding domain of the receptor VEGFR1 
and the third binding domain of the receptor VEGFR2 fused 
to the Fc portion of IgG1 (Fig.2).
Each arm of VEGF Trap-Eye binds to the binding inter-
face on each pole of the active VEGF or PlGF dimer. This 
forms a stable and inert 1:1 complex with the growth factor 
(6) uniquely binding the dimer on both sides. The Trap is 
aptly named, since the molecule isolates (or traps) the dimer, 
forming inert complexes with the growth factor (6) that do 
not interact with another VEGF Trap molecule. This blocks 
and effectively arrests the VEGF angiogenesis cascade. 
It also prevents the creation of multimeric complexes that 
can aggregate and cause immune responses in body tissues. 
VEGF Trap-Eye binds VEGF more tightly than native recep-
tors, blocking cell-surface receptor activation (7).
61
Biomed Rev 25, 2014
Aflibercept in ophthalmic neovascular disorders
INTRAOCULAR AND SYSTEMIC PHARMACOKINETIC OF 
AFLIBERCEPT
Preclinical studies on intraocular pharmacokinetics are con-
ducted on rabbits. The half-life of aflibercept in these stud-
ies was established to be 4.7 days (8). The half-life is close 
to that of bevacizumab (4.32 days), but is significant higher 
than ranibizumab (2.88 days) (9, 10). Intraocular pharmaco-
kinetics, and in particular the half-life, is related to the mo-
lecular weight of the drugs. The differences in molecular size 
of aflibercept, ranibizumab and bevacizumab are given in 
Table 2.
Aflibercept is a dimeric glycoprotein with a protein mo-
lecular weight of 97 kD, but also contains some percent of 
glycosylation, which is leading to an additional 15% of the 
total molecular mass, resulting in a total molecular weight 
of 115 kD. That is why eye pharmacokinetic behavior of 
aflibercept is similar to bevacizumab. There are limited data 
in human eyes studies, but since the intraocular half-life of a 
macromolecule is primarily determined by its molecular size, 
we could use mathematical equation to predict it. By using 
such an equation, half-life of aflibercept is estimated to be 
7.1 days (11). Experimental studies confirm a very good pen-
etrationin all layers of the retina (12). After intravitreal injec-
tion of 2 mg of aflibercept (the highest dose used in pivotal 
ophthalmologic trials), the maximum plasma concentration 
detected in 1-3 days is significantly (200-fold) lower than the 
concentration required for maximal systemic VEGF binding. 
The detection in plasma is as a free drug (a minor quantity) or 
in a complex bound with VEGF. The drug is rapidly cleared 
from circulation via pinocytotic proteolysis and glomerular 
Figure 2. Creation of fusion protein – aflibercept through fusing the second VEGF-binding domain from VEGFR1 and the third 
VEGF-binding domain from VEGFR2 to the Fc backbone of an IgG1 molecule.
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filtration after forming a complex with VEGF via the same 
pathways that metabolize antibodies. The systemic half-life 
of the unbound aflibercept is 1.5 days, which is inferior to 
that of bevacizumab (20 days) and close to the systemic half-
life of ranibizumab (6 hours) (11).
PHARMACODYNAMIC AND DOSAGE FORMS OF AFLIBERCEPT
The binding affinity of aflibercept to the VGFR-A165 as-
sessed by the equilibrium dissociation constant (Kd) was 
0.49 pM. (14) Its affinity was 19- and 181-fold higher than 
the native VEGF receptors fused to Fc (VEGFR-1, 9.33 pM 
or VEGFR-2, 88.8 pM, respectively). All three anti-VEGF 
drugs bind with high affinity to theVGFR-A165, but afliber-
cept have shown approximately 100-fold lower (i.e. the bind-
ing affinity was ~ 100-fold tighter) than that for ranibizumab 
(Kd = 46 pM) and bevacizumab (Kd = 58 pM). (14) In addi-
tion, aflibercept possesses a high binding affinityfor PlGF-2 
(Kd ~ 45 pM) (15).
Nowadays, aflibercept has ophthalmologic and oncologic 
use registration. Dosage forms that are used in ophthalmolo-
gy are preservative-free, sterile, aqueous solution in a single-
use, glass vial designed to deliver 0.05 mL (50 microliters) of 
aflibercept (40 mg/mL in 10 mM sodium phosphate, 40 mM 
sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 
6.2). The trade name, under which the product is registered, 
is Eylea® (Regeneron Pharmaceuticals, Tarrytown, NY, USA 
and Bayer, Berlin, Germany). In oncology practice the prod-
uct is registered under another generic name - ziv-aflibercept, 
with trade name Zaltrap® (Sanofi-Aventis, Paris, France 
and Regeneron Pharmaceuticals, Tarrytown, NY, USA). It 
was approved for the treatment of patients with metastatic 
colorectal cancer who had been previously treated (16). Ac-
cording to the manufacturer, this drug must not be adminis-
tered intravitreally due to its hyperosmolarity (1000 mOsm). 
The dosage that is used in ophthalmology is 100-fold lower 
than the dose allowed in oncology (4–6 mg/kg) (17).
THERAPEUTIC EFFICACY
Aflibercept is currently being approved for the treatment 
of two eye diseases: neovascular (wet) age-related macular 
degeneration (AMD) and macular edema following central 
retinal vein occlusion (CRVO).
Neovascular age-related macular degeneration
In the first clinical experience, the purpose has been to evalu-
ate the maximum tolerated dose, the bioactivity, the safety 
and tolerability of intravitreally administered aflibercept. This 
was done in Phase I study named Clinical Evaluation of Anti-
angiogenesis in the Retina Intravitreal Trial (CLEAR-IT 1) 
(18). The dosage range of aflibercept was between 0,05 – 4 
mg, which were tested on 21 patients. At 6 weeks after a single 
injection, most patients experienced an improvement in visual 
acuity (mean visual gain, 4.4 letters) and showed a decrease 
in macular thickness (−105 μm). Figure 3 shows the result 
obtained with our patient suffering from neovascular (wet) 
AMD: after treatment with aflibercept there was an almost 
50% reduction in macular thickness and almost the same per-
cent improvement in visual acuity (unpublished data).
Aflibercept is well-tolerated with no visible ocular inflam-
mation seen. In the second clinical phase (CLEAR-IT 2), the 
purpose has been to evaluate dose and dosing range interval, 
the patients (n = 159) being randomized into five treatment 
groups: the first two groups received 3 aflibercept injections 
of 0.5 mg or 2 mg monthly and the other three groups re-
ceived only one aflibercept injection of 0.5 mg, 2 mg, or 4 
mg monthly (19). The results of this clinical stage can be 
summarized as follows: (i) the reduction in macular thick-
ness experienced by the patients receiving three monthly in-
jections exceeded that of patients treated only once (20), (ii) 
patients initially treated with 2 mg every 4 weeks had the best 
visual improvement (mean gain of 9 letters) and also afliber-
cept can be applied as needed with excellent gains in vision 
(21). Thus, three different dosing schedules were identified 
for the clinical phase III studies: 0.5 mg monthly (0.5Q4), 2 
mg monthly (2Q4), or 2 mg every 2 months (2Q8) after the 
loading phase of three initial monthly doses and all of them 
compared to the standard dosing schedule for ranibizumab 
0.5 mg monthly. The studies VEGF Trap-eye Investigation 
of Efficacy and Safety in Wet AMD (VIEW) 1 and 2, have 
been conducted to evaluate efficacy of aflibercept to stan-
dard treatment – ranibizumab, against which all subsequent 
drugs should be compared. The View 1 study enrolled 1217 
patients in the US and Canada, and the View 2 study enrolled 
1240 patients in Europe, Asia, Japan, and Latin America.In 
both studies, the primary efficacy endpoint has been the pro-
portion of patients who maintained vision, defined as losing 
fewer than 15 letters of visual acuity at week 52 compared to 
baseline. Data are available through week 52. Both afliber-
cept 2Q8 and aflibercept 2Q4 groups were shown to have 
efficacy that was clinically equivalent to the ranibizumab 0.5 
mg Q4 group.In VIEW 1, patients receiving 2 mg of afliber-
cept every 4 weeks gained more vision than those receiving 
ranibizumab (+10.9 letters versus +8.1 letters; p = 0.0054) 
(22). Improvements in macular thickness were not statisti-
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cally different in the treatment groups. VIEW 2 patients re-
ceiving 2 mg of aflibercept every 8 weeks showed bimonthly 
fluctuations in macular thickness without corresponding fluc-
tuations in visual acuity (22). The safety of aflibercept was 
excellent and was comparable with that of ranibizumab in 
both the VIEW 1 and VIEW 2 studies. Severe extraocular 
adverse events such as stroke and myocardial infarction oc-
curred with similar frequencies in patients receiving afliber-
cept (0.7% and 2.6%, respectively) and in patients receiving 
ranibizumab (1.6% and 2.6%, respectively) in both VIEW 
trials. Both studies showed that all 3 regimens of aflibercept 
were noninferior to the ranibizumab monthly regimen and 
the advantages of aflibercept’s regimen are the fewer injec-
tions (no loss of efficacy) and less risk of endophthalmitis.
Macular edema following central retinal vein 
occlusion (CRVO)
Therapeutic activity of aflibercept in the treatment of macular 
edema following CRVO was proved in two phase III clinical 
studies - COPERNICUS (Controlled Phase 3 Evaluation of 
Repeated intravitreal administration of VEGF Trap-Eye In 
Central retinal vein occlusion: Utility and Safety) (23) and 
Figure 3.A Macular thickness before administration of aflibercept – 557,90 µm; B Macular thickness four weeks after admin-
istration of aflibercept – 307,00 µm;
64
Biomed Rev 25, 2014
Georgiev KD, Georgiev DD and Georgiev DS
GALILEO (General Assessment Limiting Infiltration of Ex-
udates in central retinal vein Occlusion with EYLEA) (24). 
The first six months of the both studies were identical, pa-
tients were randomized into two groups – receiving intravit-
real aflibercept 2 mg monthly and those who received intra-
vitreal placebomonthly.In the second six months,GALILEO 
study was design to continue treatment group with aflibercept 
on the PRN (provided as needed) basis and the control group 
with placebo (24), while in the COPERNICUS study (23), 
all patients were treated with aflibercept on a PRN basis.In 
both the COPERNICUS and GALILEO studies, aflibercept 
injection resulted in an improvement in visual acuity of .15 
letters in 56.1% and 60.2% of patients, respectively, at week 
24 compared with those receiving sham injections (12.3% 
and 22.1%, respectively). At week 52 in the COPERNICUS 
study, the improvement in visual acuity was 55.3% in the 
aflibercept/aflibercept PRN patients compared with 30.1% in 
the placebo/aflibercept PRN patients. In the GALILEO study, 
in which control patients did not receive any aflibercept in-
jections, the improvement was 60.2% and 32.4%, respective-
ly. The results of these studies showed that it is possible to 
maintain an excellent visual outcome and to extend the range 
of administration while using the PRN strategy. These data 
indicate that aflibercept provides benefits to patients with 
CRVO and using this drug as needed may become a first line 
approach that will reduce the burden of monthly injections.
CONCLUSION
It can be stated that aflibercept represents an attractive alter-
native to the available anti-VEGF drugs as it leads to simi-
lar improvements in visual outcomes and has a longer dura-
tion of action, due to stronger and prolonged binding to the 
VEGF-A receptor, which allows a decrease of the frequency 
of injections.
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